By: IPP Bureau
Last updated : November 18, 2026 9:16 am
TSL platform to be combined with CE-marked radiative precision hyperthermia system
Thermosome GmbH, a clinical-stage developer of targeted tumor therapies, has entered into an exclusive global licensing agreement with Cambridge, Massachusetts-based Avenor Therapeutics. The deal grants Avenor worldwide rights to Thermosome’s thermosensitive liposome (TSL) platform—encompassing seven patent families—as well as its Phase II-ready lead asset, THE001, which holds both FDA and EMA Orphan Drug Designations for soft tissue sarcomas. Financial terms of the transaction were not disclosed.
The deal builds on positive data from Thermosome’s Phase I clinical trial of its lead compound, THE001 (DPPG2-TSL-DOX). The study evaluated THE001 combined with regional hyperthermia (RHT) for patients with locally advanced, unresectable, or metastatic soft tissue sarcomas (STS) who had exhausted all prior treatments, including standard doxorubicin. Results showed a favorable safety profile, a pharmacokinetic (PK) profile confirming near-complete heat-triggered drug release, and early signs of clinical efficacy.
Avenor has also secured exclusive North American rights to a CE-marked radiative precision hyperthermia platform developed by Medlogix Srl (Rome, Italy). Avenor plans to combine this system with Thermosome’s TSL platform to advance a drug-device approach for targeted cancer therapy.
“This agreement marks an important milestone for Thermosome and the development of our proprietary TSL technology,” said Dr. Pascal Schweizer, CEO of Thermosome GmbH. “Having advanced THE001 through Phase I clinical development, we are pleased to see our technology enter a new phase with Avenor Therapeutics. The combination with an established hyperthermia system offers a promising basis for further clinical development and potentially broader applications in oncology.”
“Our vision at Avenor is to provide a new generation of heat-activated cancer therapy: precise, planned, measured with the same rigor and predictability as radiation, and able to work alongside radiotherapy, chemotherapy, immunotherapy and our own heat-activated drugs,” said Patrick Tricoli, Co-founder and CEO of Avenor. “By integrating seamlessly into existing treatment workflows, precision heat has the potential to enhance the effectiveness of cancer therapies while reducing toxicity. Thermosome’s innovative TSL technology and heat-activated drug candidate THE001 will be a perfect fit in implementing our strategy of building a leading-edge drug-device combination for targeted tumor therapy.”
Despite progress in oncology, delivering effective drug concentrations to solid tumors without causing widespread toxicity remains a major challenge. Pairing thermosensitive drugs with targeted local hyperthermia offers a promising solution. By triggering drug release directly at the tumor site, this approach increases local therapeutic exposure while sparing healthy tissue from systemic side effects. Furthermore, combining this technology with standard chemotherapy and radiotherapy creates potential synergies, paving the way for new treatments across a wider variety of solid tumors.